Welcome to our dedicated page for Ocugen news (Ticker: OCGN), a resource for investors and traders seeking the latest updates and insights on Ocugen stock.
Ocugen, Inc. (NASDAQ: OCGN) regularly issues news updates about its progress in gene therapies for blindness diseases, making its news flow particularly relevant for investors and observers of the ophthalmic biotechnology space. The company’s announcements often cover clinical trial milestones, licensing agreements, financing transactions, and participation in industry and investor conferences.
A major focus of Ocugen’s recent news has been its modifier gene therapy platform and associated programs. Updates include Phase 1, Phase 2, and Phase 2/3 data for investigational products such as OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy secondary to dry age-related macular degeneration, and OCU410ST for Stargardt disease. Press releases describe safety and exploratory efficacy findings, such as lesion growth reduction and visual function outcomes, as well as plans for future regulatory submissions.
Ocugen’s news stream also highlights business development and capital markets activity. Examples include an exclusive license agreement with Kwangdong Pharmaceutical Co., Ltd. for OCU400 in the Republic of Korea, registered direct offerings of common stock and warrants, and updates on cash runway and financial results. In addition, the company frequently announces webcasts and conference calls to discuss quarterly results, business updates, and key clinical data readouts.
Another recurring theme in Ocugen’s news is its presence at healthcare and investor conferences, such as the J.P. Morgan Healthcare Conference, NobleCon, and rare disease–focused events. These items outline presentation topics, panel participation, and the company’s messaging around its goal of advancing multiple Biologics License Application (BLA) filings within a defined timeframe.
Investors and followers of OCGN news can use this page to monitor clinical trial progress, licensing developments, financing events, and strategic communications as Ocugen advances its gene therapy programs for major retinal diseases.
Ocugen (NASDAQ: OCGN), a biotechnology company specializing in gene therapies for blindness diseases, has scheduled a conference call and live webcast for Friday, May 9, 2025, at 8:30 a.m. ET. The event will cover the company's first quarter 2025 financial results and provide business updates.
The company will release its earnings announcement before the market opens on May 9. Investors can join via phone using U.S. dial-in (800) 715-9871 or international dial-in (646) 307-1963 with Conference ID 1773288. A webcast will be available on Ocugen's investor site, with a replay accessible for approximately 45 days after the event.
Ocugen announced upcoming presentations of its modifier gene therapy platform at two major ophthalmology events: The ARVO 2025 Annual Meeting in Salt Lake City (May 4-8) and Retina World Congress in Ft. Lauderdale (May 8-11). The company will showcase three key therapies:
- OCU400 for retinitis pigmentosa (Phase 3 LiMeliGhT trial)
- OCU410ST for Stargardt disease (Phase 2/3 pivotal trial)
- OCU410 for geographic atrophy (Phase 2 ArMaDa trial)
CEO Dr. Shankar Musunuri confirmed plans to file three Biologics License Applications/Marketing Authorization Applications within three years. The presentations include clinical trial updates, safety data, and efficacy results across multiple sessions. Dr. Huma Qamar, Chief Medical Officer, will lead the company showcase at Eyecelerator and participate in panel discussions at both events.
Ocugen (NASDAQ: OCGN), a biotechnology company focused on gene therapies for blindness diseases, announced its participation in the 2025 Cell & Gene Meeting on the Mediterranean in Rome, Italy from April 15-17, 2025.
Dr. Shankar Musunuri, Chairman, CEO, and Co-founder, will present on the panel 'Commercializing ATMPs: Moving from Innovation to Market Success' on April 15 at 10:45 a.m. CEST. The presentation will highlight Ocugen's modifier gene therapy platform and its potential to offer one-time treatments for major blindness diseases.
The company's gene therapy portfolio includes:
- OCU400 for retinitis pigmentosa
- OCU410ST for Stargardt disease
- OCU410 for geographic atrophy
Ocugen (NASDAQ: OCGN) announced positive safety data from the first cohort of its Phase 1 clinical trial for OCU200, a novel fusion protein designed to treat diabetic macular edema (DME). The Data and Safety Monitoring Board (DSMB) has approved proceeding with the second cohort after reviewing safety data from the initial group.
The trial is structured as a multicenter, open-label, dose-escalation study across three cohorts: low dose (0.025 mg), medium dose (0.05 mg), and high dose (0.1 mg). Patients receive two intravitreal injections six weeks apart with a 6-month follow-up period. No serious adverse events related to OCU200 have been reported.
OCU200, combining tumstatin and transferrin proteins, targets approximately 12 million people in the US and 130 million worldwide affected by DME, diabetic retinopathy (DR), and wet age-related macular degeneration. The company aims to complete the Phase 1 trial in H2 2025, particularly addressing the 30-40% of DME patients who don't respond to current anti-VEGF therapies.
Ocugen (NASDAQ: OCGN) reported its Q4 and full year 2024 financial results, highlighting significant progress in its gene therapy programs. The company reached FDA alignment for OCU410ST's Phase 2/3 pivotal trial for Stargardt disease, potentially accelerating development by 2-3 years. Positive clinical data was reported across multiple programs:
- OCU400 showed statistically significant (p=0.005) improvement in visual function at 2-year follow-up
- OCU410 completed Phase 2 dosing with favorable safety profile
- OCU410ST demonstrated 52% slower lesion growth and significant visual improvement in Phase 1
Financial highlights include:
- Q4 2024 R&D expenses: $8.3M (vs $7.8M in Q4 2023)
- Q4 2024 net loss: $0.05 per share (vs $0.04 in Q4 2023)
- Cash position: $58.8M as of December 31, 2024
- Secured $65M in equity/debt financing in H2 2024
- Runway extended into Q1 2026